Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 278

1.

Cariprazine in the treatment of Bipolar Disorder: A systematic review and meta-analysis.

Pinto JV, Saraf G, Vigo D, Keramatian K, Chakrabarty T, Yatham LN.

Bipolar Disord. 2019 Oct 16. doi: 10.1111/bdi.12850. [Epub ahead of print]

PMID:
31618503
2.

First episode mania: we should have intervened earlier.

Jauhar S, Ratheesh A, Davey C, Yatham LN, McGorry PD, McGuire P, Berk M, Young AH.

Lancet Psychiatry. 2019 Oct;6(10):807-808. doi: 10.1016/S2215-0366(19)30340-2. No abstract available.

PMID:
31544759
3.

Affective cognition in bipolar disorder: A systematic review by the ISBD targeting cognition task force.

Miskowiak KW, Seeberg I, Kjaerstad HL, Burdick KE, Martinez-Aran A, Del Mar Bonnin C, Bowie CR, Carvalho AF, Gallagher P, Hasler G, Lafer B, López-Jaramillo C, Sumiyoshi T, McIntyre RS, Schaffer A, Porter RJ, Purdon S, Torres IJ, Yatham LN, Young AH, Kessing LV, Van Rheenen TE, Vieta E.

Bipolar Disord. 2019 Sep 6. doi: 10.1111/bdi.12834. [Epub ahead of print] Review.

PMID:
31491048
4.

An International Society of Bipolar Disorders task force report: Precursors and prodromes of bipolar disorder.

Faedda GL, Baldessarini RJ, Marangoni C, Bechdolf A, Berk M, Birmaher B, Conus P, DelBello MP, Duffy AC, Hillegers MHJ, Pfennig A, Post RM, Preisig M, Ratheesh A, Salvatore P, Tohen M, Vázquez GH, Vieta E, Yatham LN, Youngstrom EA, Van Meter A, Correll CU.

Bipolar Disord. 2019 Sep 3. doi: 10.1111/bdi.12831. [Epub ahead of print]

PMID:
31479581
5.

Machine learning and big data analytics in bipolar disorder: A position paper from the International Society for Bipolar Disorders Big Data Task Force.

Passos IC, Ballester PL, Barros RC, Librenza-Garcia D, Mwangi B, Birmaher B, Brietzke E, Hajek T, Lopez Jaramillo C, Mansur RB, Alda M, Haarman BCM, Isometsa E, Lam RW, McIntyre RS, Minuzzi L, Kessing LV, Yatham LN, Duffy A, Kapczinski F.

Bipolar Disord. 2019 Aug 29. doi: 10.1111/bdi.12828. [Epub ahead of print] Review.

PMID:
31465619
6.

Beyond evidence-based treatment of bipolar disorder: Rational pragmatic approaches to management.

Post RM, Yatham LN, Vieta E, Berk M, Nierenberg AA.

Bipolar Disord. 2019 Jul 25. doi: 10.1111/bdi.12813. [Epub ahead of print]

PMID:
31343802
7.

The case for improved care and provision of treatment for people with first-episode mania.

Jauhar S, Ratheesh A, Davey C, Yatham LN, McGorry PD, McGuire P, Berk M, Young AH.

Lancet Psychiatry. 2019 Oct;6(10):869-876. doi: 10.1016/S2215-0366(19)30082-3. Epub 2019 Jun 24. Review.

PMID:
31248840
8.

Childbirth and prevention of bipolar disorder: an opportunity for change.

Sharma V, Bergink V, Berk M, Chandra PS, Munk-Olsen T, Viguera AC, Yatham LN.

Lancet Psychiatry. 2019 Sep;6(9):786-792. doi: 10.1016/S2215-0366(19)30092-6. Epub 2019 Apr 10. Review.

PMID:
30981755
9.

Long-Acting Injectable Second-Generation/Atypical Antipsychotics for the Management of Bipolar Disorder: A Systematic Review.

Keramatian K, Chakrabarty T, Yatham LN.

CNS Drugs. 2019 May;33(5):431-456. doi: 10.1007/s40263-019-00629-z.

PMID:
30963507
10.

Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study.

Earley W, Burgess MV, Rekeda L, Dickinson R, Szatmári B, Németh G, McIntyre RS, Sachs GS, Yatham LN.

Am J Psychiatry. 2019 Jun 1;176(6):439-448. doi: 10.1176/appi.ajp.2018.18070824. Epub 2019 Mar 8.

PMID:
30845817
11.

Treatment-resistant and Multi-therapy resistant criteria for bipolar depression: consensus definition - CORRIGENDUM.

Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Di Florio A, Dietch D, Geddes JR, Goodwin GM, Grunze H, Hayes JF, Jones I, Kasper S, Macritchie K, Hamish McAllister-Williams R, Morriss R, Nayrouz S, Pappa S, Soares JC, Smith DJ, Suppes T, Talbot P, Vieta E, Watson S, Yatham LN, Young AH, Stokes PRA.

Br J Psychiatry. 2019 May;214(5):309. doi: 10.1192/bjp.2019.36. Epub 2019 Feb 28. No abstract available.

PMID:
30816078
12.

Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis.

Valdes M, Bertolin S, Qian H, Wong H, Lam RW, Yatham LN.

J Affect Disord. 2019 Mar 1;246:861-866. doi: 10.1016/j.jad.2019.01.003. Epub 2019 Jan 5.

PMID:
30795492
13.

Objective and biological markers in bipolar spectrum presentations.

Chakrabarty T, Yatham LN.

Expert Rev Neurother. 2019 Mar;19(3):195-209. doi: 10.1080/14737175.2019.1580145. Epub 2019 Feb 27.

PMID:
30761925
14.

The International Consortium Investigating Neurocognition in Bipolar Disorder (ICONIC-BD).

Burdick KE, Millett CE, Bonnín CDM, Bowie CR, Carvalho AF, Eyler LT, Gallagher P, Harvey PD, Kessing LV, Lafer B, Langenecker SA, Lewandowski KE, López-Jaramillo C, Marshall DF, Martinez-Aran A, McInnis MG, McIntyre RS, Miskowiak KW, Porter RJ, Purdon SE, Ryan KA, Sumiyoshi T, Torres IJ, Van Rheenen TE, Vieta E, Woodward ND, Yatham LN, Young A.

Bipolar Disord. 2019 Feb;21(1):6-10. doi: 10.1111/bdi.12748. No abstract available.

PMID:
30720913
15.

Relationship between work functioning and self-reported cognitive complaints in patients with major depressive disorder treated with desvenlafaxine.

Alonso-Prieto E, Rubino C, Lucey M, Evans VC, Tam EM, Woo C, Iverson GL, Chakrabarty T, Yatham LN, Lam RW.

Psychiatry Res. 2019 Feb;272:144-148. doi: 10.1016/j.psychres.2018.12.062. Epub 2018 Dec 10.

PMID:
30583256
16.

WFSBP guidelines on how to grade treatment evidence for clinical guideline development.

Hasan A, Bandelow B, Yatham LN, Berk M, Falkai P, Möller HJ, Kasper S; WFSBP Guideline Task Force Chairs.

World J Biol Psychiatry. 2019 Jan;20(1):2-16. doi: 10.1080/15622975.2018.1557346. Epub 2019 Feb 4. Review.

PMID:
30526182
17.

Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition.

Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Florio AD, Dietch D, Geddes JR, Goodwin GM, Grunze H, Hayes JF, Jones I, Kasper S, Macritchie K, McAllister-Williams RH, Morriss R, Nayrouz S, Pappa S, Soares JC, Smith DJ, Suppes T, Talbot P, Vieta E, Watson S, Yatham LN, Young AH, Stokes PRA.

Br J Psychiatry. 2019 Jan;214(1):27-35. doi: 10.1192/bjp.2018.257. Epub 2018 Dec 6. Erratum in: Br J Psychiatry. 2019 May;214(5):309.

PMID:
30520709
18.

Inflammatory cytokines and cognitive functioning in early-stage bipolar I disorder.

Chakrabarty T, Torres IJ, Bond DJ, Yatham LN.

J Affect Disord. 2019 Feb 15;245:679-685. doi: 10.1016/j.jad.2018.11.018. Epub 2018 Nov 6.

PMID:
30447566
19.

Weight gain as a predictor of frontal and temporal lobe volume loss in bipolar disorder: A prospective MRI study.

Bond DJ, Su W, Honer WG, Dhanoa T, Batres-Y-Carr T, Lee SS, Torres IJ, Lam RW, Yatham LN.

Bipolar Disord. 2019 Feb;21(1):50-60. doi: 10.1111/bdi.12722. Epub 2018 Dec 1.

PMID:
30422375
20.

Revising Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, criteria for the bipolar disorders: Phase I of the AREDOC project.

Parker G, Tavella G, Macqueen G, Berk M, Grunze H, Deckersbach T, Dunner DL, Sajatovic M, Amsterdam JD, Ketter TA, Yatham LN, Kessing LV, Bassett D, Zimmerman M, Fountoulakis KN, Duffy A, Alda M, Calkin C, Sharma V, Anand A, Singh MK, Hajek T, Boyce P, Frey BN, Castle DJ, Young AH, Vieta E, Rybakowski JK, Swartz HA, Schaffer A, Murray G, Bayes A, Lam RW, Bora E, Post RM, Ostacher MJ, Lafer B, Cleare AJ, Burdick KE, O'Donovan C, Ortiz A, Henry C, Kanba S, Rosenblat JD, Parikh SV, Bond DJ, Grunebaum MF, Frangou S, Goldberg JF, Orum M, Osser DN, Frye MA, McIntyre RS, Fagiolini A, Manicavasagar V, Carlson GA, Malhi GS.

Aust N Z J Psychiatry. 2018 Oct 31:4867418808382. doi: 10.1177/0004867418808382. [Epub ahead of print]

PMID:
30378461
21.

Appetitive Symptoms Differentially Predict Treatment Response to Fluoxetine, Light, and Placebo in Nonseasonal Major Depression.

Levitan RD, Levitt AJ, Michalak EE, Morehouse R, Ramasubbu R, Yatham LN, Tam EM, Lam RW.

J Clin Psychiatry. 2018 Jul 24;79(4). pii: 17m11856. doi: 10.4088/JCP.17m11856.

PMID:
30063303
22.

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M.

Bipolar Disord. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609. Epub 2018 Mar 14.

23.

Biomarkers in mood disorders: Are we there yet?

Quevedo J, Yatham LN.

J Affect Disord. 2018 Jun;233:1-2. doi: 10.1016/j.jad.2018.01.002. Epub 2018 Jan 10. No abstract available.

PMID:
29395259
24.

Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians.

Miskowiak KW, Burdick KE, Martinez-Aran A, Bonnin CM, Bowie CR, Carvalho AF, Gallagher P, Lafer B, López-Jaramillo C, Sumiyoshi T, McIntyre RS, Schaffer A, Porter RJ, Purdon S, Torres IJ, Yatham LN, Young AH, Kessing LV, Vieta E.

Bipolar Disord. 2018 May;20(3):184-194. doi: 10.1111/bdi.12595. Epub 2018 Jan 18. Review.

PMID:
29345040
25.

Psychometric properties of the well-being index (WHO-5) spanish version in a sample of euthymic patients with bipolar disorder.

Bonnín CM, Yatham LN, Michalak EE, Martínez-Arán A, Dhanoa T, Torres I, Santos-Pascual C, Valls E, Carvalho AF, Sánchez-Moreno J, Valentí M, Grande I, Hidalgo-Mazzei D, Vieta E, Reinares M.

J Affect Disord. 2018 Mar 1;228:153-159. doi: 10.1016/j.jad.2017.12.006. Epub 2017 Dec 6.

PMID:
29248821
26.

Cognitive functioning in first episode bipolar I disorder patients with and without history of psychosis.

Trisha C, Golnoush A, Jan-Marie K, Torres IJ, Yatham LN.

J Affect Disord. 2018 Feb;227:109-116. doi: 10.1016/j.jad.2017.10.003. Epub 2017 Oct 2.

PMID:
29055258
27.

Clinically relevant response and remission outcomes in cariprazine-treated patients with bipolar I disorder.

Earley W, Durgam S, Lu K, Ruth A, Németh G, Laszlovszky I, Yatham LN.

J Affect Disord. 2018 Jan 15;226:239-244. doi: 10.1016/j.jad.2017.09.040. Epub 2017 Sep 25.

28.

A Positron Emission Tomography Study of Norepinephrine Transporter Occupancy and Its Correlation with Symptom Response in Depressed Patients Treated with Quetiapine XR.

Yatham LN, Sossi V, Ding YS, Vafai N, Arumugham SS, Dhanoa T, Lam RW, Bond DJ, Puyat JH.

Int J Neuropsychopharmacol. 2018 Feb 1;21(2):108-113. doi: 10.1093/ijnp/pyx066.

29.

Staging in bipolar disorder: from theoretical framework to clinical utility.

Berk M, Post R, Ratheesh A, Gliddon E, Singh A, Vieta E, Carvalho AF, Ashton MM, Berk L, Cotton SM, McGorry PD, Fernandes BS, Yatham LN, Dodd S.

World Psychiatry. 2017 Oct;16(3):236-244. doi: 10.1002/wps.20441.

30.

Quality of life in bipolar disorder: towards a dynamic understanding.

Morton E, Murray G, Michalak EE, Lam RW, Beaulieu S, Sharma V, Cervantes P, Parikh SV, Yatham LN.

Psychol Med. 2018 May;48(7):1111-1118. doi: 10.1017/S0033291717002495. Epub 2017 Sep 18.

PMID:
28918761
31.

Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force.

Miskowiak KW, Burdick KE, Martinez-Aran A, Bonnin CM, Bowie CR, Carvalho AF, Gallagher P, Lafer B, López-Jaramillo C, Sumiyoshi T, McIntyre RS, Schaffer A, Porter RJ, Torres IJ, Yatham LN, Young AH, Kessing LV, Vieta E.

Bipolar Disord. 2017 Dec;19(8):614-626. doi: 10.1111/bdi.12534. Epub 2017 Sep 12.

32.

The impact of fatigue and energy on work functioning and impairment in patients with major depressive disorder treated with desvenlafaxine.

Sarfati D, Evans VC, Tam EM, Woo C, Iverson GL, Yatham LN, Lam RW.

Int Clin Psychopharmacol. 2017 Nov;32(6):343-349. doi: 10.1097/YIC.0000000000000192.

PMID:
28763344
33.

Subcortical structural volumes in recently remitted first episode mania.

Arumugham SS, Torres IJ, Lang DJ, Su W, Lam RW, Honer WG, Yatham LN.

J Affect Disord. 2017 Nov;222:23-27. doi: 10.1016/j.jad.2017.06.051. Epub 2017 Jun 24.

PMID:
28667890
34.

Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-analysis.

McGirr A, Berlim MT, Bond DJ, Chan PY, Yatham LN, Lam RW.

Br J Psychiatry. 2017 Jun;210(6):403-407. doi: 10.1192/bjp.bp.116.195826. Epub 2017 Apr 6. Review.

PMID:
28385704
35.

Diagnosis and body mass index effects on hippocampal volumes and neurochemistry in bipolar disorder.

Bond DJ, Silveira LE, MacMillan EL, Torres IJ, Lang DJ, Su W, Honer WG, Lam RW, Yatham LN.

Transl Psychiatry. 2017 Mar 28;7(3):e1071. doi: 10.1038/tp.2017.42.

36.

Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies.

Earley W, Durgam S, Lu K, Debelle M, Laszlovszky I, Vieta E, Yatham LN.

J Affect Disord. 2017 Jun;215:205-212. doi: 10.1016/j.jad.2017.03.032. Epub 2017 Mar 9.

37.

Telomere Length, Oxidative Stress, Inflammation and BDNF Levels in Siblings of Patients with Bipolar Disorder: Implications for Accelerated Cellular Aging.

Vasconcelos-Moreno MP, Fries GR, Gubert C, Dos Santos BTMQ, Fijtman A, Sartori J, Ferrari P, Grun LK, Parisi MM, Guma FTCR, Barbé-Tuana FM, Kapczinski F, Rosa AR, Yatham LN, Kauer-Sant'Anna M.

Int J Neuropsychopharmacol. 2017 Jun 1;20(6):445-454. doi: 10.1093/ijnp/pyx001.

38.

Self-poisoning suicide deaths in people with bipolar disorder: characterizing a subgroup and identifying treatment patterns.

Schaffer A, Weinstock LM, Sinyor M, Reis C, Goldstein BI, Yatham LN, Levitt AJ.

Int J Bipolar Disord. 2017 Dec;5(1):16. doi: 10.1186/s40345-017-0081-9. Epub 2017 May 11.

39.

Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study.

Yatham LN, Mackala S, Basivireddy J, Ahn S, Walji N, Hu C, Lam RW, Torres IJ.

Lancet Psychiatry. 2017 Mar;4(3):208-217. doi: 10.1016/S2215-0366(17)30046-9. Epub 2017 Feb 7. Erratum in: Lancet Psychiatry. 2017 Mar;4(3):185.

PMID:
28185899
40.

Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials.

McGirr A, Vöhringer PA, Ghaemi SN, Lam RW, Yatham LN.

Lancet Psychiatry. 2016 Dec;3(12):1138-1146. doi: 10.1016/S2215-0366(16)30264-4. Epub 2016 Oct 26. Review.

PMID:
28100425
41.

Lower cognitive functioning as a predictor of weight gain in bipolar disorder: a 12-month study.

Bond DJ, Torres IJ, Lee SS, Kozicky JM, Silveira LE, Dhanoa T, Lam RW, Yatham LN.

Acta Psychiatr Scand. 2017 Mar;135(3):239-249. doi: 10.1111/acps.12674. Epub 2016 Dec 20.

PMID:
27995622
42.

The effect of remission status on work functioning in employed patients treated for major depressive disorder.

Sarfati D, Stewart K, Woo C, Parikh SV, Yatham LN, Lam RW.

Ann Clin Psychiatry. 2017 Feb;29(1):11-16.

PMID:
27901522
43.

S-adenosyl methionine (SAMe) for depression in adults.

Galizia I, Oldani L, Macritchie K, Amari E, Dougall D, Jones TN, Lam RW, Massei GJ, Yatham LN, Young AH.

Cochrane Database Syst Rev. 2016 Oct 10;10:CD011286. Review.

44.

Trajectories of body mass index change in first episode of mania: 3-year data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).

Hu C, Torres IJ, Qian H, Wong H, Halli P, Dhanoa T, Ahn S, Wang G, Bond DJ, Lam RW, Yatham LN.

J Affect Disord. 2017 Jan 15;208:291-297. doi: 10.1016/j.jad.2016.08.048. Epub 2016 Oct 11.

PMID:
27794253
45.

A Longitudinal Study of the Relationships Between Mood Symptoms, Body Mass Index, and Serum Adipokines in Bipolar Disorder.

Bond DJ, Andreazza AC, Hughes J, Dhanoa T, Torres IJ, Kozicky JM, Young LT, Lam RW, Yatham LN.

J Clin Psychiatry. 2017 Apr;78(4):441-448. doi: 10.4088/JCP.15m10189.

PMID:
27780338
46.

Structural brain changes in first episode mania with and without psychosis: Data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).

Keramatian K, Dhanoa T, McGirr A, Lang DJ, Honer WG, Lam RW, Yatham LN.

World J Biol Psychiatry. 2018;19(sup2):S30-S40. doi: 10.1080/15622975.2016.1249950. Epub 2016 Dec 8.

PMID:
27762161
47.

Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first-episode mania and association with clinical outcome.

Kozicky JM, McGirr A, Bond DJ, Gonzalez M, Silveira LE, Keramatian K, Torres IJ, Lam RW, Yatham LN.

Bipolar Disord. 2016 Sep;18(6):511-519. doi: 10.1111/bdi.12437.

PMID:
27759214
48.

Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 5. Complementary and Alternative Medicine Treatments.

Ravindran AV, Balneaves LG, Faulkner G, Ortiz A, McIntosh D, Morehouse RL, Ravindran L, Yatham LN, Kennedy SH, Lam RW, MacQueen GM, Milev RV, Parikh SV; CANMAT Depression Work Group.

Can J Psychiatry. 2016 Sep;61(9):576-87. doi: 10.1177/0706743716660290. Epub 2016 Aug 2. Review.

49.

The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder.

Lam RW, Iverson GL, Evans VC, Yatham LN, Stewart K, Tam EM, Axler A, Woo C.

J Affect Disord. 2016 Oct;203:55-61. doi: 10.1016/j.jad.2016.05.074. Epub 2016 May 31.

PMID:
27280963
50.

Metacognitive knowledge and experience in recently diagnosed patients with bipolar disorder.

Torres IJ, Mackala SA, Kozicky JM, Yatham LN.

J Clin Exp Neuropsychol. 2016 Sep;38(7):730-44. doi: 10.1080/13803395.2016.1161733. Epub 2016 May 4.

PMID:
27144722

Supplemental Content

Loading ...
Support Center